ALK and non-small cell lung carcinoma: Notwithstanding these limitations, the findings from this network meta-analysis represent the most comprehensive currently available evidence base for initial choice about first-line immunotherapies for advanced NSCLC patients without known EGFR mutations or ALK translocations.